ANALYSIS OF HUMAN BRADYKININ RECEPTOR GENE
AND ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE
POLYMORPHISMS IN END-STAGE RENAL DISEASE
AMONG MALAYSIANS
Vasudevan R, Ismail P, Jaafar NI, Mohamad NA, Etemad E, Wan Aliaa WS, Eshkor S
a These authors contributed equally to this article.
*Corresponding Author: Professor Dr. Patimah Ismail, Department of Biomedical Sciences, Faculty of Medical and Health
Science, Universiti Putra Malaysia, Serdang 43400, Selangor DE, Malaysia. Tel.: +60-3-8947-2314. Fax: +60-3-8943-6178.
E-mail: patimashimail@gmail.com and Dr. Ramachandran Vasudevan, Institute of Gerontology, Universiti Putra Malaysia,
Serdang, Selangor DE, 43400, Malaysia. Tel.: +60-3-8947-2752. Fax: +60-3-8947-2738. E-mail: vasuphd@gmail.com.
page: 37
download article in pdf format
|
|
Abstract
The aim of this study was to determine the
association of the c.894G>T; p.Glu298Asp polymorphism
and the variable number tandem repeat
(VNTR) polymorphism of the endothelial nitric oxide
synthase (eNOS) gene and c.181C>T polymorphism
of the bradykinin type 2 receptor gene (B2R) in
Malaysian end-stage renal disease (ESRD) subjects.
A total of 150 ESRD patients were recruited from
the National Kidney Foundation’s (NKF)dialysis
centers in Malaysia and compared with 150 normal
healthy individuals. Genomic DNA was extracted
from buccal cells of all the subjects. The polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP) method was carried out to amplify
the products and the restricted fragments were separated
by agarose gel electrophoresis. Statistical analyses
were carried out using software where a level of
p <0.05 was considered to be statistically significant.
The genotypic and allelic frequencies of the B2R
gene (c.181C>T, 4b/a) and eNOS gene (c.894G>T)
polymorphisms were not statistically significant
(p >0.05) when compared to the control subjects.
The B2R and eNOS gene polymorphisms may not
be considered as genetic susceptibility markers for
Malaysian ESRD subjects.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
